US Patent
US10441630 — Topical formulations and uses thereof
Formulation · Assigned to Sun Pharma Global FZE · Expires 2033-08-23 · 7y remaining
Vulnerability score
42/100
Strong — defensible against typical IPR challenges
What this patent protects
This patent protects topical formulations, including ophthalmic formulations, for treating or preventing diseases or conditions.
USPTO Abstract
Provided herein include formulations for topical administration, such as ophthalmic formulations, and methods of using such formulations. In some aspects and embodiments the formulations may include a polyoxyl lipid or fatty acid, and or a polyalkoxylated alcohol and may include nanomicelles. Also include methods of treating or preventing diseases or conditions, such as ocular diseases or conditions.
Drugs covered by this patent
- Sandimmune (cyclosporine) · Novartis AG (originally Sandoz)
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.